Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

HROWM 01.07.2025

Full Press ReleaseSEC FilingsOur HROWM Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Amir Shojaei
  • 01.07.2025 - Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
  • 11.21.2024 - Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Recent Filings

  • 01.21.2025 - 8-K Current report
  • 01.08.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.08.2025 - 3 Initial statement of beneficial ownership of securities
PDF Version

NASHVILLE, Tenn.--(BUSINESS WIRE)--Jan. 7, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced thatAmir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences,Dr. Shojaeibrings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications.

Dr. Shojaeimost recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. Prior to that, he held senior executive roles at leading pharmaceutical companies, including CEO ofTherOptix Corporation, where he advanced a novel drug-eluting contact lens platform, and in various leadership roles atNovartis PharmaceuticalsandShire Pharmaceuticals(acquired by Takeda). In 2013, while atShire Pharmaceuticals,Dr. Shojaeiwas instrumental in the clinical development and the eventual FDA approval of Xiidra®, the first product approved to treat both the signs and symptoms of dry eye disease (DED). This milestone achievement revolutionized the DED landscape, solidified his reputation as a visionary leader in ophthalmology, and paved the way for next-generation DED products likeVEVYE, which Harrow launched last year.

“We are thrilled to welcomeDr. Shojaeito Harrow,” saidMark L. Baum, Chief Executive Officer of Harrow. “His exceptional scientific acumen, regulatory expertise, and proven track record of driving commercial innovation in eyecare align seamlessly with our mission to make eyecare solutions accessible and affordable. As we leverage our growing presence as a leading North American ophthalmic pharmaceutical company, we are confident that under Dr. Shojaei’s leadership, Harrow will continue to push the boundaries of what’s possible in preserving and enhancing the gift of sight.”

Dr. Shojaeiearned his PharmD and PhD in Pharmaceutical Sciences from theUniversity of the Pacific. With multiple patents, over 25 peer-reviewed publications, and extensive experience in both the anterior and posterior segments of ophthalmology and other therapeutic areas, he is uniquely positioned to lead Harrow’s next phase of growth.

Dr. ShojaeisucceedsDennis E. Saadeh, PharmD, who is retiring after nearly a decade of service to Harrow, including his most recent role as CSO.

“Since joining Harrow in 2015, Dennis has been a true partner and a driving force behind our success,” Baum continued. “Dennis has been somewhat of an unsung hero in our industry, pioneering the development of all our market-leading compounded products – sight-saving, affordable, and accessible treatments relied upon by thousands of eyecare professionals and millions of Americans. Dennis’s impact on patient care over the past decade cannot be overstated, and his unwavering dedication to our mission has helped establish the real-world scientific excellence that defines Harrow’s approach to serving the ophthalmic community. We honor his enduring legacy with deep gratitude and admiration as we celebrate his remarkable career. Although he will continue to consult with Harrow, we are happy Dennis will have more time to spend with his family and pursue other exciting opportunities.”

About Harrow

Harrow, Inc.(Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visitharrow.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of theU.S.Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with theSecurities and Exchange Commission(SEC), including its Annual Report on Form 10-K for the year endedDecember 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with theSEC. Such documents may be read free of charge on the SEC’s web site atsec.gov. Undue reliance should not be placed on forward‐looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250107043710/en/

InvestorsJamie WebbDirector of Communications and Investor Relationsjwebb@harrowinc.com615-733-4737

MediaDeb HollidayHolliday Communications, Inc.deb@hollidaycommunications.net412-877-4519

Source:Harrow, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com